SFA Therapeutics
sfatherapeutics.com
Actively hiring
Health Care
Immunology & Inflammation Therapeutics
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
501-1000
employees, estimated range
Backers
1
Y Combinator
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 4, 2023
Certified SFA Therapeutics Announces FDA Clearance of IND Application for SFA-001N for the Treatment of NASH and Fibrosis · wavy.com
Jun 2021
Went through Y Combinator
Tractionpublic signals, read monthly
Web presence
top 7%
of 133.2M domains by links, Common Crawl
Registers and programsofficial lists and records that name the company
| Legal entity | Use SFA Therapeutics Inc. | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
Y Combinator Similar startupsby what they do, their industry and backers
Decoding Human T issue Biology to C reate Revolutionary T herapeutics. TRexBio is developing immunoregulatory medicines designed to restore…
Oblenio Bio is pursuing broad immune reset as a transformative therapy for refractory autoimmune diseases through our LBL-051 T-cell…
Quell Therapeutics is a clinical-stage company, fuelled by curiosity and discovery, on a mission to make life better for those battling…
Abivax is a clinical-stage biotechnology company driven to advance human health by regulating the immune response through the power of…
Coultreon Biopharma is a clinical-stage biotech company developing next-generation precision medicines for immunology and autoimmune…
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation biologics for severe immune-mediated inflammatory…
Overview
SFA Therapeutics is developing a next-generation oral immune tolerance therapy for psoriasis. Our investigational approach is designed to restore immune tolerance at its source, targeting the underlying immune dysfunction rather than broadly suppressing the immune system.
News
SFA Therapeutics, Inc Intellectual Property Update Newswise
SFA Therapeutics, Inc. is pleased to announce issuance of United States Patent No. 12,622,885, directed to a deuterated form of short chain fatty acid compounds and their therapeutic uses. U.S. 12,622,885 issued May 12, 2026, providing key New Chemical En
Read more
Report
SFA Therapeutics: Interview With CEO Dr. Ira Spector About The Biotech Company
SFA Therapeutics is a clinical-stage biotech company novel oral small-molecule biosynthetic compounds derived from human microbial metabolites. This immuno-modulation platform is used to develop therapeutic agents that mitigate inflammation without causin
Read more
Report
SFA Therapeutics Strengthens Intellectual Property In Autoimmune Disease And Hepatocellular Carcinoma
Read more
Report